Thrombosen der Vena cava inferior – Ursachen und therapeutische Implikationen

Thrombosen, die die Vena cava inferior (VCI) betreffen bzw. involvieren, sind selten. Häufig ist die VCI nicht allein betroffen, sondern es finden sich auch Thrombosen, die aus den zuführenden Venensystemen wie Leber-, Nieren-, Ovarial- oder Becken-Beinvenen aszendiert sind. Gefäßanomalien, Autoimmun- und Tumorerkrankungen sind ätiologisch von Bedeutung. Je nach zugrunde liegender Pathologie ergeben sich Implikationen für die Therapiestrategie.

Abstract

Thromboses affecting or involving the inferior vena cava (VCI) are rare. Frequently, the VCI is not alone affected, but there are also thromboses that have ascended from the afferent venous systems such as the liver, kidneys, ovaries, or pelvic leg veins. Most abnormalities are discovered incidentally when abdominal imaging is performed for other reasons. Individuals with a congenital anomaly of the VCI have an increased risk of developing thrombosis at a young age. In addition, every 5th venous thromboembolism (VTE) is associated with cancer. Tumor diseases can contribute to thrombogenesis in the VCI through space-occupying processes. The most common tumor entities include renal cell carcinoma and other malignancies of the urogenital tract. Therapeutic anticoagulation is the therapy of choice, with direct oral anticoagulants (DOAC) being the preferred choice today. Mechanical revascularization procedures are particularly indicated to young patients, although evidence of a better long-term outcome is still lacking. The therapeutic strategy depends on the underlying pathology and must take all individual factors into account.

Kernaussagen

• Bei etwa 1–3 % aller Patienten mit einer tiefen Venenthrombose der unteren Extremitäten liegt eine VCI-Beteiligung vor.

• Patienten mit VCI-Thrombose sind durchschnittlich jünger als Patienten mit einer isolierten Beinvenenthrombose.

• Es lassen sich angeborene und erworbene Ursachen unterscheiden, wobei oftmals mehrere Faktoren zugleich vorliegen (multifaktorielle Thrombogenese).

• Die meisten Anomalien werden zufällig entdeckt, wenn eine abdominelle Bildgebung aus anderen Gründen durchgeführt wird.

• Personen mit kongenitaler Anomalie der VCI haben ein erhöhtes Risiko, bereits in jungen Jahren eine Thrombose zu entwickeln.

• Jede 5. venöse Thromboembolie (VTE) tritt malignomassoziiert auf.

• Tumorerkrankungen können durch raumfordernde Prozessen zur Thrombogenese in der VCI beitragen.

• Zu den häufigsten Tumorentitäten zählen dabei das Nierenzellkarzinom und andere Malignome des Urogenitaltrakts.

• Eine therapeutische Antikoagulation gilt als Therapie der Wahl, wobei heutzutage vorzugsweise direkte orale Antikoagulanzien (DOAK) eingesetzt werden.

• Mechanische Revaskularisationsverfahren sind besonders bei jungen Patienten indiziert, wobei weiterhin der überzeugende Nachweis eines besseren Langzeitverlaufs fehlt.

Schlüsselwörter

Antiphospholipidsyndrom - kongenitale Gefäßanomalie - Nierenzellkarzinom - Thrombose - Vena cava inferior

Keywords

antiphospholipid syndrome - congenital vascular anomaly - renal cell carcinoma - thrombosis - inferior vena cava

Publication History

Article published online:
29 August 2022

• Literatur

• 1 Agnelli G, Verso M, Ageno W. et al. The MASTER registry on venous thromboembolism: Description of the study cohort. Thrombosis Research 2008; 121: 605-610
• 2 Stein PD, Matta F, Yaekoub AY. Incidence of Vena Cava Thrombosis in the United States. The American Journal of Cardiology 2008; 102: 927-929
• 3 Cohen O, Ageno W, Farjat AE. et al. Management strategies and clinical outcomes in patients with inferior vena cava thrombosis: Data from GARFIELD‐VTE. J of Thrombosis Haemost 2022; 20: 366-374
• 4 Kraft C, Hecking C, Schwonberg J. et al. Patients with inferior vena cava thrombosis frequently present with lower back pain and bilateral lower-extremity deep vein thrombosis. Vasa 2013; 42 (04) 275-283
• 5 Shafi I, Hassan AA, Akers KG. et al. Clinical and procedural implications of congenital vena cava anomalies in adults: A systematic review. International Journal of Cardiology 2020; 315: 29-35
• 6 Kraft C, Schuettfort G, Weil Y. et al. Thrombosis of the inferior vena cava and malignant disease. Thrombosis Research 2014; 134: 668-673
• 7 Obernosterer A, Aschauer M, Schnedl W. et al. Anomalies of the Inferior Vena Cava in Patients with Iliac Venous Thrombosis. Ann Intern Med 2002; 136: 37
• 8 Chee Y-L, Culligan DJ, Watson HG. Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young. British Journal of Haematology 2001; 114: 878-880
• 9 Li SJ, Lee J, Hall J. et al. The inferior vena cava: anatomical variants and acquired pathologies. Insights Imaging 2021; 12
• 10 Kim JH, Ha HK, Yoon K-H. et al. CT Features of Abdominal Manifestations of Primary Antiphospholipid Syndrome. Journal of Computer Assisted Tomography 1999; 23: 678-683
• 11 Kaushik S, Federle MP, Schur PH. et al. Abdominal Thrombotic and Ischemic Manifestations of the Antiphospholipid Antibody Syndrome: CT Findings in 42 Patients. Radiology 2001; 218: 768-771
• 12 Espinosa G, Font J, García-Pagan JC. et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Medicine (Baltimore) 2001; 80: 345-354
• 13 Linnemann B. Antiphospholipid syndrome – an update. Vasa 2018; 47: 451-464
• 14 Risitano AM, Peffault de Latour R. How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the future. Br J Haematol 2022; 196: 288-303
• 15 Radke PW, Schwarz ER, Groesdonk H. et al. Thrombosis in Behcet's disease: report of a case followed by a systematic review using the methodology of evidence-based medicine. J Thromb Thrombolysis 2001; 11: 137-141
• 16 Chen J, Yao X. A Contemporary Review of Behcet’s Syndrome. Clinic Rev Allerg Immunol 2021; 61: 363-376
• 17 Peisen F, Thaiss WM, Ekert K. et al. Retroperitoneale Fibrose und ihre Differenzialdiagnosen: Die Rolle der radiologischen Bildgebung. Rofo 2020; 192: 929-936
• 18 Fenaroli P, Maritati F, Vaglio A. Into Clinical Practice: Diagnosis and Therapy of Retroperitoneal Fibrosis. Curr Rheumatol Rep 2021; 23
• 19 Wang K, Wang Z, Zeng Q. et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One 2021; 16: e0245601
• 20 Nguyen GC, Bernstein CN, Bitton A. et al. Consensus Statements on the Risk, Prevention, and Treatment of Venous Thromboembolism in Inflammatory Bowel Disease: Canadian Association of Gastroenterology. Gastroenterology 2014; 146: 835-848.e6
• 21 Cohen JB, Comer DM, Yabes JG. et al. Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample Study. TH Open 2020; 04: e51-e58
• 22 Sharma AP, Devana SK, Tyagi S. et al. Isolated renal vein and inferior vena cava thrombosis in a young man with ulcerative colitis: diagnostic challenges and lessons learned. BMJ Case Rep 2020; 13
• 23 Köksal AŞ, Ertugrul I, Dişibeyaz S. et al. Crohn’s and Behçet’s Disease Association Presenting with Superior Vena Cava Thrombosis. Dig Dis Sci 2005; 50: 1698-1701
• 24 Papa A, Tursi A, Danese S. et al. Venous Thromboembolism in Patients with Inflammatory Bowel Disease: The Role of Pharmacological Therapy and Surgery. JCM 2020; 9: 2115
• 25 Hernández-Gea V, de Gottardi A, Leebeek FW. et al. Current knowledge in pathophysiology and management of Budd-Chiari syndrome and non-cirrhotic non-tumoral splanchnic vein thrombosis. Journal of Hepatology 2019; 71: 175-199
• 26 Wang ZG, Zhang FJ, Yi MQ. et al. Evolution of management for Budd-Chiari syndrome: a team's view from 2564 patients. ANZ J Surg 2005; 75: 55-63
• 27 Singhal R, Brimble KS. Thromboembolic complications in the nephrotic syndrome: Pathophysiology and clinical management. Thrombosis Research 2006; 118: 397-407
• 28 Barbour SJ, Greenwald A, Djurdjev O. et al. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney International 2012; 81: 190-195
• 29 Delahunt B, Eble JN, Samaratunga H. et al. Staging of renal cell carcinoma: current progress and potential advances. Pathology 2021; 53: 120-128
• 30 Alfuhaid TR, Khalili K, Kirpalani A. et al. Neoplasms of the inferior vena cava--pictorial essay. Can Assoc Radiol J 2005; 56: 140-147
• 31 Wachtel H, Gupta M, Bartlett EK. et al. Outcomes after resection of leiomyosarcomas of the inferior vena cava: A pooled data analysis of 377 cases. Surgical Oncology 2015; 24: 21-27
• 32 Wang MX, Menias CO, Elsherif SB. et al. Current update on IVC leiomyosarcoma. Abdom Radiol 2021; 46: 5284-5296
• 33 Alkhouli M, Morad M, Narins CR. et al. Inferior Vena Cava Thrombosis. JACC: Cardiovascular Interventions 2016; 9: 629-643
• 34 Grewal S, Chamarthy MR, Kalva SP. Complications of inferior vena cava filters. Cardiovasc. Diagn. Ther 2016; 6: 632-641
• 35 Konstantinides SV, Meyer G, Becattini C. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J 2020; 41: 543-603
• 36 Stevens SM, Woller SC, Kreuziger LB. et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest 2021; 160: e545-e608
• 37 McAree BJ, O'Donnell ME, Fitzmaurice GJ. et al. Inferior vena cava thrombosis: a review of current practice. Vasc Med 2013; 18: 32-43